Literature DB >> 3620272

A comparison of isoxicam pharmacokinetics in young and elderly subjects.

C F George, A G Renwick, A S Darragh, J Hosie, D Blake, W van Marle, G J Frank.   

Abstract

1 The pharmacokinetics of isoxicam have been compared in 57 volunteers with an average age of 31.3 years and 48 elderly subjects with an average age of 71.9 years. 2 Isoxicam was given in a single daily dose of 200 mg for up to 22 days. Similar plasma concentrations were obtained in the two age groups, average maximum concentrations being 39.7 mg l-1 in those under 65 and 38.1 mg l-1 in the elderly. There were no significant differences in the half-life which averaged 30.4 and 32.1 h respectively. 3 Approximately 9% of all those studied had half-life values in excess of 50 h. The results are consistent with the possibility of genetic polymorphism of isoxicam hydroxylation. 4 It is concluded that isoxicam is suitable for use in once daily dosage and that there are no clinically significant differences in its pharmacokinetics between young and elderly subjects.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3620272      PMCID: PMC1400956          DOI: 10.1111/j.1365-2125.1986.tb02994.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  Study of fatal bone marrow depression with special reference to phenylbutazone and oxyphenbutazone.

Authors:  W H Inman
Journal:  Br Med J       Date:  1977-06-11

2.  Use of medicines in general practice.

Authors:  D C Skegg; R Doll; J Perry
Journal:  Br Med J       Date:  1977-06-18

3.  Cross-national study of the extent of anti-anxiety-sedative drug use.

Authors:  M B Balter; J Levine; D I Manheimer
Journal:  N Engl J Med       Date:  1974-04-04       Impact factor: 91.245

4.  Drug prescribing and use in an American community.

Authors:  P D Stolley; M H Becker; J D McEvilla; L Lasagna; M Gainor; L M Sloane
Journal:  Ann Intern Med       Date:  1972-04       Impact factor: 25.391

5.  Pharmocogenetic implications of polymorphic debrisoquine hydroxylations.

Authors:  M D Rawlins
Journal:  Q J Med       Date:  1985-02

6.  Jaundice associated with the use of benoxaprofen.

Authors:  B M Goudie; G F Birnie; G Watkinson; R N MacSween; L H Kissen; N E Cunningham
Journal:  Lancet       Date:  1982-04-24       Impact factor: 79.321

7.  Fatal cholestatic jaundice in elderly patients taking benoxaprofen.

Authors:  H M Taggart; J M Alderdice
Journal:  Br Med J (Clin Res Ed)       Date:  1982-05-08

8.  Medicines and elderly people: a general practice survey.

Authors:  R Law; C Chalmers
Journal:  Br Med J       Date:  1976-03-06

9.  The pharmacokinetics of benoxaprofen in elderly subjects.

Authors:  R C Hamdy; B Murnane; N Perera; K Woodcock; I M Koch
Journal:  Eur J Rheumatol Inflamm       Date:  1982

10.  Predisposing factors in adverse reactions to drugs.

Authors:  N Hurwitz
Journal:  Br Med J       Date:  1969-03-01
View more
  1 in total

Review 1.  Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.

Authors:  K T Olkkola; A V Brunetto; M J Mattila
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.